Cargando…
Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
Biosimilars are biological medicines that are approved via stringently defined regulatory pathways on the basis that comparable safety, efficacy, and quality have been demonstrated to their reference medicine. The advantage of biosimilar drugs is that they may be less expensive than the reference me...
Autores principales: | Goldsmith, David, Dellanna, Frank, Schiestl, Martin, Krendyukov, Andriy, Combe, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5951862/ https://www.ncbi.nlm.nih.gov/pubmed/29500617 http://dx.doi.org/10.1007/s40261-018-0637-1 |
Ejemplares similares
-
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018) -
Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
por: London, Gérard, et al.
Publicado: (2018) -
HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
por: Dellanna, Frank, et al.
Publicado: (2017) -
Extrapolation concept at work with biosimilar: a decade of experience in oncology
por: Krendyukov, Andriy, et al.
Publicado: (2018) -
The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information
por: Schiestl, Martin, et al.
Publicado: (2017)